13,567 Shares in Vera Therapeutics, Inc. $VERA Acquired by GC Wealth Management RIA LLC

Key Points

• GC Wealth Management RIA LLC acquired 13,567 shares of Vera Therapeutics, valued at approximately $320,000, during the 2nd quarter, indicating growing interest from institutional investors in the company.
• The company has a consensus rating of "Moderate Buy" from analysts, with seven recommending a "Buy" and an average price target of $63.00.
• Vera Therapeutics reported a loss of ($1.20) earnings per share for the last quarter, missing analysts' expectations, and forecasts indicate a projected annual loss of -2.89 EPS.

GC Wealth Management RIA LLC purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,567 shares of the company's stock, valued at approximately $320,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP lifted its position in Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after acquiring an additional 500 shares in the last quarter. AlphaQuest LLC lifted its position in Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock worth $96,000 after acquiring an additional 3,213 shares in the last quarter. Fifth Third Bancorp acquired a new position in Vera Therapeutics during the 2nd quarter worth approximately $102,000. GAMMA Investing LLC increased its holdings in Vera Therapeutics by 1,779.1% during the 1st quarter. GAMMA Investing LLC now owns 8,287 shares of the company's stock worth $199,000 after purchasing an additional 7,846 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Vera Therapeutics by 19.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company's stock worth $229,000 after purchasing an additional 1,572 shares during the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Vera Therapeutics in a report on Thursday, September 18th. JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Finally, Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a report on Monday, August 4th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Trading Down 0.9%

NASDAQ:VERA opened at $28.79 on Thursday. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61. The firm has a market capitalization of $1.84 billion, a P/E ratio of -8.04 and a beta of 1.23. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The business has a 50 day simple moving average of $23.13 and a 200 day simple moving average of $23.08.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter last year, the business posted ($0.62) earnings per share. Equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.